Linear growth of children with X-linked hypophosphatemia treated with burosumab: a real-life observational study

[1]  G. Baroncelli,et al.  Burosumab for X-linked hypophosphatemia in children and adolescents: Opinion based on early experience in seven European countries , 2023, Frontiers in Endocrinology.

[2]  C. Audrain,et al.  Growth pattern in children with X-linked hypophosphatemia treated with burosumab and growth hormone , 2022, Orphanet Journal of Rare Diseases.

[3]  F. Di Serio,et al.  Determination of iFGF23 Upper Reference Limits (URL) in healthy pediatric population, for its better correct use , 2022, Frontiers in Endocrinology.

[4]  J. Salles,et al.  Growth hormone treatment improves final height in children with X-linked hypophosphatemia , 2022, Orphanet journal of rare diseases.

[5]  F. Glorieux,et al.  Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia , 2022, The Journal of clinical endocrinology and metabolism.

[6]  A. Siafarikas,et al.  Clinical practice guidelines for paediatric X‐linked hypophosphataemia in the era of burosumab , 2022, Journal of paediatrics and child health.

[7]  M. Sharafinski,et al.  Real-world effectiveness of burosumab in children with X-linked hypophosphatemic rickets , 2022, Pediatric Nephrology.

[8]  M. Whyte,et al.  Sustained Efficacy and Safety of Burosumab, a Monoclonal Antibody to FGF23, in Children With X-Linked Hypophosphatemia , 2021, The Journal of clinical endocrinology and metabolism.

[9]  S. Mora,et al.  X-Linked Hypophosphatemic Rickets: Multisystemic Disorder in Children Requiring Multidisciplinary Management , 2021, Frontiers in Endocrinology.

[10]  W. Högler,et al.  Monitoring response to conventional treatment in children with XLH: Value of ALP and Rickets Severity Score (RSS) in a real world setting. , 2021, Bone.

[11]  Y. Seino,et al.  Switching from conventional therapy to burosumab injection has the potential to prevent nephrocalcinosis in patients with X-linked hypophosphatemic rickets , 2021, Journal of pediatric endocrinology & metabolism : JPEM.

[12]  L. Zeitlin,et al.  Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy , 2021, Therapeutic advances in endocrinology and metabolism.

[13]  F. Glorieux,et al.  Patient-Reported Outcomes from a Randomized, Active-Controlled, Open-Label, Phase 3 Trial of Burosumab Versus Conventional Therapy in Children with X-Linked Hypophosphatemia , 2021, Calcified Tissue International.

[14]  F. Santos Rodríguez X-Linked Hypophosphataemic Rickets and Growth , 2020, Advances in Therapy.

[15]  J. S. San Martin,et al.  Growth Curves for Children with X-linked Hypophosphatemia , 2019, The Journal of clinical endocrinology and metabolism.

[16]  L. Rejnmark,et al.  Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia , 2019, Nature Reviews Nephrology.

[17]  J. S. San Martin,et al.  Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: Utility of the radiographic Rickets Severity Score. , 2019, Bone.

[18]  K. White,et al.  Pharmacological management of X-linked hypophosphataemia. , 2018, British journal of clinical pharmacology.

[19]  M. Collins Burosumab: At Long Last, an Effective Treatment for FGF23‐Associated Hypophosphatemia , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  D. Haffner,et al.  Effects of growth hormone treatment on adult height in severely short children with X-linked hypophosphatemic rickets , 2018, Pediatric Nephrology.

[21]  J. Salles,et al.  Two-year recombinant human growth hormone (rhGH) treatment is more effective in pre-pubertal compared to pubertal short children with X-linked hypophosphatemic rickets (XLHR). , 2017, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[22]  M. Kuro-o,et al.  FGF23-αKlotho as a paradigm for a kidney-bone network. , 2017, Bone.

[23]  F. Glorieux,et al.  Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. , 2015, The Journal of clinical endocrinology and metabolism.

[24]  S. Ellard,et al.  Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment , 2012, Pediatric Nephrology.

[25]  D. Fischer,et al.  Three-year growth hormone treatment in short children with X-linked hypophosphatemic rickets: effects on linear growth and body disproportion. , 2011, The Journal of clinical endocrinology and metabolism.

[26]  D. Haffner,et al.  Age-related stature and linear body segments in children with X-linked hypophosphatemic rickets , 2011, Pediatric Nephrology.

[27]  D. Haffner,et al.  Effects of growth hormone treatment on body proportions and final height among small children with X-linked hypophosphatemic rickets. , 2004, Pediatrics.

[28]  O. Mäkitie,et al.  Early treatment improves growth and biochemical and radiographic outcome in X-linked hypophosphatemic rickets. , 2003, The Journal of clinical endocrinology and metabolism.

[29]  G. Saggese,et al.  Effect of growth hormone treatment on final height, phosphate metabolism, and bone mineral density in children with X-linked hypophosphatemic rickets. , 2001, The Journal of pediatrics.

[30]  B. Manaster,et al.  Radiographic scoring method for the assessment of the severity of nutritional rickets. , 2000, Journal of tropical pediatrics.

[31]  R. B. Payne,et al.  Renal Tubular Reabsorption of Phosphate (TmP/GFR): Indications and Interpretation , 1998, Annals of clinical biochemistry.

[32]  OUP accepted manuscript , 2021, Nephrology Dialysis Transplantation.